Zinbryta (daclizumab) / Biogen, AbbVie - LARVOL DELTA

Induction immunosuppression strategy and long-term graft and patient survival in contemporary adult liver transplantation: A United States allocation-era reassessment (TTS 2026) - "Induction regimens were categorized as none, antithymocyte globulin (ATG), or interleukin-2 receptor antagonists (IL-2RA; basiliximab/daclizumab). Maintenance immunosuppression at discharge was classified as CNI-only, CNI+steroids, CNI+mycophenolate mofetil (MMF), or triple therapy (CNI+MMF+steroids)... Induction practice remains heterogeneous across U.S. adult liver transplantation. ATG induction was associated with improved graft and patient survival and fewer hospitalizations, whereas IL-2RA was associated with higher rates of rejection and rehospitalization without a survival benefit. These findings support risk-informed induction selection and prospective evaluation of optimal induction and maintenance combinations."

Clinical • Transplant Rejection • Transplantation • IL2RA

What is the evidence on immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis? - A Cochrane Review summary with commentary. (PubMed, NeuroRehabilitation) - "High-certainty evidence suggests that natalizumab largely reduces relapses at 12 (RR 0.52, 95% CI 0.43 to 0.63) and 24 months (RR 0.56, 95% CI 0.48 to 0.65), and cladribine (RR 0.53, 95% CI 0.44 to 0.64) and alemtuzumab (RR 0.57, 95% CI 0.47 to 0.68) largely reduce relapses at 24 months. People taking fingolimod, teriflunomide, glatiramer acetate, interferon beta-1a, laquinimod, natalizumab and daclizumab are more likely to discontinue the drug because of unwanted effects. Lack of data for treatment effects beyond two years and poor reporting of adverse events in short-term trials limit the applicability of these findings."

Journal • Review • CNS Disorders • Multiple Sclerosis

Impact of Induction Therapy Choice on Acute Rejection and Infection Outcomes After Kidney Transplantation: A Bayesian Network Meta-Analysis (ATC 2026) - "Interleukin-2 receptor antagonists (IL-2RA), lymphocyte-depleting antibodies such as rabbit antithymocyte globulin (rATG), and alemtuzumab have all been utilized, but direct comparative data on efficacy and infection risk are limited.* A Bayesian network meta-analysis was performed to compare the efficacy and safety of various induction immunosuppressive agents in adult kidney transplant recipients...Studies comparing basiliximab, daclizumab, alemtuzumab, and rATG (± corticosteroids) were included... The choice of induction therapy significantly affects immunologic and infectious outcomes after kidney transplantation. Alemtuzumab demonstrated the most favorable balance between efficacy and safety, showing superior protection against acute rejection without increasing infection risk. In contrast, rATG was linked to higher BK viral infections."

Retrospective data • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Neutropenia • Thrombocytopenia • Transplant Rejection • Transplantation • IL2RA

Establishment of the Utrecht Transplant Cohort: A Dynamic Registry of Kidney Transplant Recipients (ERA 2026) - "At one year follow-up the majority received tacrolimus (93%) and mycophenolate (73%) as maintenance immunosuppression; induction therapy included basiliximab or daclizumab in 46% and alemtuzumab in 4% of cases. The dynamic nature of this cohort facilitates robust longitudinal research and improved patient monitoring. Using automated data-extraction allows for significantly faster and less resource-intensive data extraction compared to traditional registries, even while navigating the vastly larger data volume."

Clinical • Transplantation

Benefits and Risks of Induction Immunosuppression in Pediatric Autoimmune Liver Disease from SPLIT Database (ATC 2026) - "Induction therapy with Basiliximab or Daclizumab significantly reduces the incidence of biopsy-confirmed acute rejection within the first 30 days following pediatric liver transplantation for AILD. Conversely, ATG is associated with a significantly higher risk of culture-proven infections between days 30 and 90 post-transplant. Our findings suggest that Interleukin IL-2 receptor antagonists effectively prevent early rejection without increasing the risk of infection, PTLD, disease recurrence, graft loss, or mortality."

Clinical • Late-breaking abstract • Autoimmune Hepatitis • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hepatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Transplant Rejection • IL2

A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE ON THERAPIES FOR MODERATE APLASTIC ANEMIA (EHA 2026) - "Treatment choices include supportive care, monotherapy (cyclosporine [CSA], tacrolimus, daclizumab, thrombopoietin receptor agonists [TPO-RA], androgens), double or triple therapy, (combining horse or rabbit anti-thymocyte globulin [hATG or rATG], CSA/tacrolimus, and eltrombopag [EPAG]/TPO-RA or androgens), and/or hematopoietic stem-cell transplantation (HSCT). Due to varied timepoints, missing data, and cohort selection, there was insufficient homogenous data for quantitative analysis. This SLR demonstrates a clear need for uniform definition of mAA and for comparative, prospective studies to enable the comparison of therapeutic effectiveness and to develop sufficient treatment algorithms."

Clinical • HEOR • Real-world • Real-world evidence • Review • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders

Epigenetic histone deacetylase inhibition by sodium butyrate reduces neuroinflammation, improves neurological dysfunction and promotes disease modification of epileptogenesis following traumatic brain injury. (PubMed, Exp Neurol) - "These results support that SB, by targeting injury-induced HDAC hyperactivation during the latent period, interrupts maladaptive epigenetic and neuroinflammatory cascades, thereby reducing progression to chronic epilepsy and neurological dysfunction. Collectively, these findings demonstrate HDAC inhibition as a viable neuroprotective and disease-modifying strategy, offering a promising therapeutic avenue to mitigate epilepsy burden and improve neurological recovery following TBI."

Journal • CNS Disorders • Epilepsy • Inflammation • Psychiatry • Vascular Neurology

Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review. (PubMed, J Neurol) - "Monoclonal antibodies are an effective option in RRMS, with clinical and radiological benefits superior to those of conventional treatments. Their use requires individualized assessment and close follow-up due to the risk of adverse effects, especially in high-risk patients."

Clinical • Journal • Review • CNS Disorders • Immunology • Infectious Disease • Multiple Sclerosis

T2* mapping in magnetic resonance imaging for stratifying the hypoxic microenvironment in pancreatic ductal adenocarcinoma: a preliminary study. (PubMed, Quant Imaging Med Surg) - "Hypoxia-inducible factor-1α (HIF-1α) expression was used to evaluate PDAC hypoxia levels, and patients were stratified into low and high hypoxia groups...High-hypoxia tumors were associated with poorer differentiation (P<0.001). T2* mapping may serve as a noninvasive imaging biomarker for stratifying the hypoxic microenvironment in PDAC."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • HIF1A

A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE ON THERAPIES FOR MODERATE APLASTIC ANAEMIA (EBMT 2026) - "Treatment choices depend on blood counts, transfusion dependency or other significant symptoms and include supportive care, monotherapy (cyclosporine [CSA], tacrolimus, daclizumab, thrombopoietin receptor agonists [TPO-RA], androgens), double or triple therapy, (combining horse or rabbit anti-thymocyte globulin [hATG or rATG], CSA/tacrolimus, and eltrombopag [EPAG]/TPO-RA or androgens), and/or haematopoietic stem-cell transplantation (HSCT)... Across heterogenous studies, OS and ORR have been documented for monotherapies, double, and triple therapies; HSCT was only reported in small, heterogeneous cohorts. Due to varied timepoints, missing data, and cohort selection, there was insufficient homogenous data for quantitative analysis. This SLR demonstrates a clear need for uniform definition of mAA and for comparative, prospective studies to enable the comparison of therapeutic effectiveness and to develop sufficient treatment algorithms."

Clinical • HEOR • Real-world • Real-world evidence • Review • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders

A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE ON THERAPIES FOR MODERATE APLASTIC ANAEMIA (EBMT 2026) - "Treatment choices depend on blood counts, transfusion dependency or other significant symptoms and include supportive care, monotherapy (cyclosporine [CSA], tacrolimus, daclizumab, thrombopoietin receptor agonists [TPO-RA], androgens), double or triple therapy, (combining horse or rabbit anti-thymocyte globulin [hATG or rATG], CSA/tacrolimus, and eltrombopag [EPAG]/TPO-RA or androgens), and/or haematopoietic stem-cell transplantation (HSCT)... Across heterogenous studies, OS and ORR have been documented for monotherapies, double, and triple therapies; HSCT was only reported in small, heterogeneous cohorts. Due to varied timepoints, missing data, and cohort selection, there was insufficient homogenous data for quantitative analysis. This SLR demonstrates a clear need for uniform definition of mAA and for comparative, prospective studies to enable the comparison of therapeutic effectiveness and to develop sufficient treatment algorithms."

Clinical • HEOR • Real-world • Real-world evidence • Review • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders

COMPREHENSIVE ANALYSIS OF THE IMMUNE RESPONSE PROGRESSION OF THE ADDITION OF IL-2RΑ ANTAGONISTS ON T CELLS IN ACUTE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS (EBMT 2026) - " A fully MHC-mismatched aGVHD model was established, and recipient mice were randomized into a control group (saline), a standard prophylaxis group (tacrolimus/mycophenolate mofetil/ methotrexate), and an IL-2RA (daclizumab) plus standard prophylaxis group. This study demonstrates that a 4-dose IL-2RA regimen combined with standard prophylaxis regulates T-cell immune responses through multi-faceted mechanisms, effectively controlling aGVHD while preserving the GVL effect, providing a potential therapeutic strategy for clinical aGVHD prophylaxis."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • CD8 • IL2RA

COMPREHENSIVE ANALYSIS OF THE IMMUNE RESPONSE PROGRESSION OF THE ADDITION OF IL-2RΑ ANTAGONISTS ON T CELLS IN ACUTE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS (EBMT 2026) - " A fully MHC-mismatched aGVHD model was established, and recipient mice were randomized into a control group (saline), a standard prophylaxis group (tacrolimus/mycophenolate mofetil/ methotrexate), and an IL-2RA (daclizumab) plus standard prophylaxis group. This study demonstrates that a 4-dose IL-2RA regimen combined with standard prophylaxis regulates T-cell immune responses through multi-faceted mechanisms, effectively controlling aGVHD while preserving the GVL effect, providing a potential therapeutic strategy for clinical aGVHD prophylaxis."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • CD8 • IL2RA

Interleukin-2 Receptor Antagonist Induction Therapy in Lung Transplantation-A Meta-Analysis of Reconstructed Time-to-Event Data. (PubMed, J Clin Med) - "Induction therapy with interleukin-2 receptor antagonists (IL2-AR), such as basiliximab and daclizumab, is designed to reduce acute rejection and improve graft survival...Studies comparing IL2-AR induction with antithymocyte globulin (ATG), alemtuzumab, or no induction therapy were included...No significant differences were found for freedom from acute rejection (p = 0.774) or secondary outcomes, including freedom from BOS (p = 0.455), hospital LOS (p = 0.423), and time until extubation (p = 0.186). IL2-AR therapy may be associated with improved survival after lung transplantation; however, evidence remains inconclusive due to heterogeneity and limitations in study design."

Journal • Retrospective data • Review • Pulmonary Disease • Respiratory Diseases • Transplant Rejection • Transplantation

Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis. (PubMed, Int Immunopharmacol) - "Our study provides genetic evidence supporting a causal role for immune cell-specific genes in AD susceptibility. The 14 hub genes and associated druggable targets establish a foundation for precision immunotherapy development in AD."

IO biomarker • Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • CD4 • CD52 • HLA-C • HLA-DQB1 • HLA-DQB2 • IL2RA

No Association of Sex or Racial Factors With Outcomes in Adult Intestine-Only Transplant: A United Network for Organ Sharing Database Analysis. (PubMed, Exp Clin Transplant) - "Recipient age and basiliximab/daclizumab may significantly influence adult intestine-only transplant recipient survival but not graft outcomes."

Journal • Retrospective data • Transplantation

In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment. (PubMed, Cell Rep) - "We defined key tumor heterogeneity features, including the presence of mixed KRAS mutations and tertiary lymphoid structures, identifying biomarkers that distinguish the latter from lymph nodes. Lastly, by leveraging patient, cell, and mouse data, we determined which aspects of tumor biology are recapitulated in bulk datasets and reductionist models."

Journal • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Daclizumab enhances aGVHD prophylaxis by modulating T-cell polarization while preserving the graft-versus-lymphoma effect (ASH 2025) - "Our prior clinical data showed that adding Daclizumab, an anti-CD25 monoclonal antibody, to standard prophylaxis (Mycophenolate mofetil/Tacrolimus/Methotrexate) significantly reduced grade 3–4 aGvHD incidence in thalassemia patients undergoing alternative donor HSCT. Daclizumab enhances aGvHD prophylaxis by modulating T-cell polarization—favoring Th2/Treg balance and reducing cytotoxicity—while preserving graft-versus-lymphoma effects. These findings support anti-CD25 antibodies as a promising strategy to optimize immune tolerance and anti-tumor efficacy post-transplantation."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • CD4 • CD69 • CD8 • GZMB • IFNG • IL17A • IL2 • IL4 • PRF1

Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial (ASH 2025) - "Anti-CD25 mAb demonstrates established efficacy in treatingmultiple sclerosis and preventing post-transplant rejection, with a favorable toxicity profile.This trial evaluated the efficacy and safety of anti-CD25 mAb (Daclizumab) in patients with HLH who hadnot responded to previous dexamethasone-based therapy. It had low toxicityand was well tolerated. This novel treatment is promising and merits further investigation in a largercohort."

Clinical • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Multiple Sclerosis • Rare Diseases • Respiratory Diseases • Transplant Rejection • IL2

Targeted Therapies and Pharmacologic Advances in Mucous Membrane Pemphigoid: A Comprehensive Review. (PubMed, Dermatol Pract Concept) - "Considering the severity of the condition, progressive fibrosis, and resistance to therapy, more research is required in relation to the pathogenesis of MMP and the efficacy and safety profile of novel pharmacological options. Pharmacological agents should provide the achievement and maintenance of remission with minimal adverse effects. A broader spectrum of pharmacological agents will allow a personalized approach and more alternatives, in particular for recalcitrant cases, failure of the previous therapy, and in patients with MMP and malignancy."

Journal • Review • Dermatology • Fibrosis • Immunology • Infectious Disease • Oncology

Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Related Haploidentical Donor and Unrelated Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China (ASH 2023) - "This study aimed to investigate whether Daclizumab at a dose of 1 mg/Kg on days +7, +14, +28 and +42 reduced GVHD plus standard GVHD prophylaxis (tacrolimus [FK506] plus methotrexate [MTX] and mycophenolate mofetil [MMF]) in TM patients with HID-HSCT or MUD-HSCT. The results of our study analysis suggest that Daclizumab at a dose of 1 mg/kg on days +7, +14, +28 and +42 provides clinically meaningful benefits when added to standard GVHD prophylaxis in TM patients undergoing haploidentical donor and unrelated donor transplantation, including decrease in the incidence rate of aGVHD without sever infection and transplant-related complications. Four doses of Daclizumab should be included in the GVHD prophylaxis of patients with thalassemia major selected for related haploidentical donor and unrelated donor transplantation."

Retrospective data • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Respiratory Diseases • Transplantation

Comparative Oncology: Cross-Sectional Single-Cell Transcriptomic Profiling of the Tumor Microenvironment Across Seven Human Cancers. (PubMed, Cancers (Basel)) - "The competitive receptor ACKR1 was minimally expressed on endothelial cells, consistent with PDAC hypo-vascularity...Differential interactions and the presence of "dominant signaling cell populations " with dominant outgoing signals may underlie the heterogeneity in tumor aggressiveness across these cancers. Comparative scRNA-seq analysis of multiple cancers reveals distinct tumor phenotypes and cell-cell communication patterns, offering insights into the molecular architecture of human solid tumors."

Biomarker • Journal • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma • Thyroid Gland Carcinoma • ACKR1 • CAFs • CXCR1 • CXCR2 • EPCAM • IGF1 • RGS5

Retrospective Comparison of Kidney Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Patients with Systemic Sclerosis (KIDNEY WEEK 2025) - "Results There were statistically significant worse outcomes in graft survival in SSc patients receiving induction therapy with alemtuzamab (AB), and thymo+basiliximab/thymo+daclizumab as well as with maintenance prednisone (MP). A 2005 case study documented two SRC recurrences, with the earlier event occurring in the patient on higher steroid doses. Hazard ratios of graft and patient survival comparing different induction methods and maintenance prednisone among SSc cohort"

Retrospective data • Immunology • Scleroderma • Systemic Sclerosis • Transplantation

Incidence, Patterns, and Outcomes of Fungal Infections in Patients with Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation (ASH 2024) - "GVHD prophylaxis regimens included cyclosporine (n=116), tacrolimus or sirolimus (n=11), mycophenolate mofetil (MMF, n=125) and daclizumab (n=8). The pooled overall mortality rate due to IFIs was 23.6% (95% CI : 0.06-0.58, I2 =86.3%).CONCLUSION : Invasive fungal infections lead to significant mortality in patients with GVHD, with a higher incidence in acute GVHD as compared to chronic GVHD. Available literature is very heterogeneous, and our findings underscore the need for further research in this area."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Candidiasis • Chronic Graft versus Host Disease • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Transplantation

Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China (ASH 2024) - "This study aimed to investigate whether administering Daclizumab at a dose of 1 mg/kg on days +7, +14, +28, and +42, in addition to standard GvHD prophylaxis (tacrolimus [FK506], methotrexate [MTX], and mycophenolate mofetil [MMF]), reduces the incidence of GvHD in TM patients undergoing alternative donor HSCT...The conditioning regimen for all patients included busulfan (Bu, 1mg/kg i.v. 4x daily on days -9 to -6), cyclophosphamide (Cy, 50mg/kg i.v. once daily, days -5 to -2), fludarabine (Flu, 50mg/m² i.v. once daily from days -12 to -10), and anti-thymocyte globulin (ATG, 2.5mg/kg i.v. once daily, days -4 to -1). Sixty-six (39.05%) patients received letermovir in prophylaxis of cytomegalovirus (CMV) infection, including 65 in the Daclizumab group and 1 in the control group...The use of Daclizumab significantly reduced clinically relevant grade 3-4 aGvHD without increasing severe infections or transplant related complications, also improved post-transplant TGFS...."

Retrospective data • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Transplantation